Application of liquid biopsy-based targeted capture sequencing analysis to improve the precision treatment of non-small cell lung cancer by tyrosine kinase inhibitors
Crossref DOI link: https://doi.org/10.1136/bmjresp-2021-001154
Published Online: 2022-01-28
Published Print: 2022-01
Update policy: https://doi.org/10.1136/crossmarkpolicy
Zhang, Lei
Coffin, John
Formenti, Kim
Chu, Quincy
Izevbaye, Iyare
Funding for this research was provided by:
Hoffmann - La Roche
AstraZeneca
License valid from 2022-01-27